Guest NikoleV Posted September 4, 2012 Share Posted September 4, 2012 ASCO Highlights: Dr. Socinski on Management of EGFR wild type, and SCLC September 1st, 2012 - by Dr. Jack West http://blog.lungevity.org/2012/09/01/so ... lc-update/ Here are the last two podcast summary pieces by Dr. Mark Socinski on lung cancer highlights from ASCO 20120. The first here reviewed the TAILOR trial, an Italian study directly comparing second line Taxotere (docetaxel) to Tarceva (erlotinib) in advanced NSCLC patients without an EGFR mutation. Though the trial has generated significant discussion in the lung cancer community, it is been criticized in its real value, and Dr. Socinski will share several reasons why. Below, you’ll find the audio and video versions of the podcast along with the transcript and figures. (Click the link above to get the audio and video links) Dr. Socinski ASCO 2012 LC Highlights TAILOR Video Podcast Dr. Socinski ASCO 2012 LC Highlights TAILOR Audio Podcast Dr. Socinski ASCO 2012 LC Highlights TAILOR Transcript Dr. Socinski ASCO 2012 LC Highlights TAILOR Figures The last subject he covered was small cell lung cancer, specifically two important trials presented at ASCO 2012. The first was a SWOG trial of the standard second line agent topotecan (here given on a weekly schedule) either alone or combined with the antiangiogenic agent Eylea (aflibercept). The results of this trial were generally considered encouraging enough to warrant further study, and you can learn the details from his talk. He also covers an important study done by the Japanese Cooperative Oncology Group (JCOG), which compared cisplatin/amrubicin to cisplatin/irinotecan, which is standard first line therapy for extensive stage SCLC in Japan. Dr. Socinski reviews the results and places them in context for us. Below is the video and audio versions of the podcast, along with the transcript and figures. Dr. Socinski ASCO 2012 LC Highlights SCLC Video Podcast Dr. Socinski ASCO 2012 LC Highlights SCLC Audio Podcast Dr. Socinski ASCO 2012 LC Highlights SCLC Transcript Dr. Socinski ASCO 2012 LC Highlights SCLC Figures Dr. Socinski covered just the first half of our collection of ASCO lung cancer highlights. We’ll follow very soon with Dr. Joel Neal’s coverage of a wide range of promising novel agents for lung cancer in the next series of podcasts. Look for those soon! Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.